Welcome to the international HTA database

Showing [23806 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2015	NIHR Health Technology Assessment programme	The clinical effectiveness and cost-effectiveness of telephone triage for managing same-day consultation requests in general practice: a cluster randomised controlled trial comparing general practitioner-led and nurse-led management systems with usual care (the ESTEEM trial)
2015	NIHR Health Technology Assessment programme	Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation
2015	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Umeclidinium (Incruse®)
2015	NIHR Health Services and Delivery Research programme	The organisation and delivery of health improvement in general practice and primary care: a scoping study
2015	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Enzalutamide (Xtandi®)
2015	HAYES, Inc.	Primary endovascular mechanical thrombectomy for treatment of acute ischemic stroke
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Patiromer for hyperkalaemia – first line
2015	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Regorafenib: benefit assessment according to §35a Social Code Book V]
2015	German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI)	[Interventions to improve health-related behaviours of men]
2015	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Leuprorelin acetate (Prostap® SR DCS/Prostap® 3 DCS)
2015	Agency for Healthcare Research and Quality (AHRQ)	Treatment of nonmetastatic muscle-invasive bladder cancer
2015	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Tacrolimus (Envarsus®)
2015	HAYES, Inc.	Second-wave direct-acting antivirals for hepatitis C: Simeprevir
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Alectinib for advanced ALK-positive, non-small cell lung cancer – first line
2015	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Dabrafenib (new therapeutic indication): benefit assessment according to §35a Social Code Book V]
2015	NIHR Health Technology Assessment programme	Evaluating Long-term Outcomes of NHS Stop Smoking Services (ELONS): a prospective cohort study
2015	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Olodaterol (as hydrochloride) (Striverdi® Respimat®)
2015	Agency for Healthcare Research and Quality (AHRQ)	Genetic testing for developmental disabilities, intellectual disability, and autism spectrum disorder
2015	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Pomalidomide (Imnovid®)
2015	HAYES, Inc.	Sonohysterography for assessment of abnormal uterine bleeding
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Alectinib for locally advanced or metastatic ALK-positive, non-small cell lung cancer following failure of crizotinib
2015	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Trametinib: benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Cabozantinib (Cometriq®)
2015	Health Council of the Netherlands Gezondheidsraad (GR)	Determining death in postmortal organ donation. Protocols and criteria, including an updated Brain Death Protocol
2015	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Brimonidine (Mirvaso®)
2015	HAYES, Inc.	Spinal cord stimulation for relief of neuropathic pain
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Atezolizumab for locally advanced or metastatic non-small cell lung cancer – second line
2015	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Follitropin alfa (Bemfola®)
2015	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Beclometasone dipropionate/formoterol fumarate (Fostair®)
2015	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Magnesium aspartate dihydrate (Magnaspartate)
2015	HAYES, Inc.	Staged approach to sacral nerve stimulation for treatment of fecal incontinence
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Bavituximab for advanced non-small cell lung cancer – second line in combination with docetaxel
2015	NIHR Health Technology Assessment programme	Total hip replacement and surface replacement for the treatment of pain and disability resulting from end-stage arthritis of the hip (review of technology appraisal guidance 2 and 44): systematic review and economic evaluation
2015	Agency for Healthcare Research and Quality (AHRQ)	Relationship between use of quality measures and improved outcomes in serious mental illness
2015	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Lurasidone (Latuda®)
2015	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Brentuximab vedotin (Adcetris®)
2015	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Rarunavir/cobicistat (Rezolsta®)
2015	HAYES, Inc.	Total pancreatectomy with islet autotransplantation for chronic pancreatitis
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Bevacizumab (Avastin) with erlotinib (Tarceva) for EGFR positive, advanced or metastatic non-small cell lung cancer – first line
2015	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Infliximab (Remsima®)
2015	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Adalimumab (Humira®)
2015	Blue Cross Blue Shield Association (BCBS)	Special report: chromosomal microarray for the genetic evaluation of patients with global developmental delay, intellectual disability, and autism spectrum disorder
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Dabrafenib (Tafinlar) and trametinib (Mekinist) combination therapy for metastatic BRAF V600E positive non-small cell lung cancer
2015	NIHR Health Technology Assessment programme	Surgical Trial In Traumatic intraCerebral Haemorrhage (STITCH): a randomised controlled trial of Early Surgery compared with Initial Conservative Treatment
2015	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Infliximab (Inflectra®)
2015	NIHR Health Technology Assessment programme	LDK378 for previously treated anaplastic-lymphoma-kinase-positive non-small-cell lung cancer [ID729]
2015	Belgian Health Care Knowledge Centre (KCE)	Autologous breast reconstruction techniques after mammary resection time measurements for a potential re-evaluation of the surgeon fee
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Daratumumab monotherapy for relapsed and refractory multiple myeloma
2015	NIHR Health Technology Assessment programme	A systematic review and economic evaluation of intraoperative tests [RD-100i one-step nucleic acid amplification (OSNA) system and Metasin test] for detecting sentinel lymph node metastases in breast cancer
2015	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Umeclidinium/vilanterol (as trifenatate) (Anoro® Ellipta®)
2015	NIHR Health Technology Assessment programme	Development of processes allowing near real-time refinement and validation of triage tools during the early stage of an outbreak in readiness for surge: the FLU-CATs Study
2015	Canadian Agency for Drugs and Technologies in Health (CADTH)	Perceval S sutureless valve for aortic valve replacement: a review of the clinical effectiveness, safety, and cost-effectiveness
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Daratumumab with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma
2015	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Dolutegravir/abacavir/lamivudine (Triumeq®)
2015	NIHR Health Services and Delivery Research programme	Measuring prevalence, reliability and variation in high-risk prescribing in general practice using multilevel modelling of observational data in a population database
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Gemtuzumab ozogamicin (Mylotarg) with conventional chemotherapy for acute myeloid leukaemia – first line
2015	Institute for Clinical Effectiveness and Health Policy (IECS)	Corneal endothelial keratoplasty for the treatment of corneal endothelial dysfunction
2015	NIHR Health Technology Assessment programme	The clinical effectiveness and cost-effectiveness of STeroids Or Pentoxifylline for Alcoholic Hepatitis (STOPAH): a 2 × 2 factorial randomised controlled trial
2015	NIHR Health Technology Assessment programme	Pre-hospital non-invasive ventilation for acute respiratory failure: a systematic review and cost-effectiveness evaluation
2015	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Bedaquiline (Sirturo®)
2015	National Evidence-based Healthcare Collaborating Agency (NECA)	[Development of a preference-based instrument: Asian Comparative Study]
2015	Canadian Agency for Drugs and Technologies in Health (CADTH)	Rituximab for granulomatosis with polyangiitis or microscopic polyangiitis: a review of the clinical and cost-effectiveness
2015	NIHR Horizon Scanning Centre (NIHR HSC)	MABp1 (Xilonix) for metastatic colorectal cancer –third line
2015	Institute for Clinical Effectiveness and Health Policy (IECS)	Equine therapy and other Equine-related therapies in developmental disorders, autism spectrum disorders and cerebral palsy
2015	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Entecavir (Baraclude®)
2015	National Evidence-based Healthcare Collaborating Agency (NECA)	[Economic evaluation of carotid artery stenting compared with carotid endarterectomy in patients with carotid artery stenosis]
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Obinutuzumab (Gazyvaro) for indolent non-Hodgkin lymphoma – first line, in combination with chemotherapy
2015	Institute for Clinical Effectiveness and Health Policy (IECS)	[Hair micro transplant using follicular unit extraction technique for alopecia]
2015	Basque Office for Health Technology Assessment (OSTEBA)	[An evaluation of the efficacy of psychosocial techniques (cognitive rehabilitation vs. psychoeducation) as an additional treatment to pharmacological treatment in bipolar disorder]
2015	NIHR Health Technology Assessment programme	A systematic review and economic evaluation of exercise referral schemes in primary care: a short report
2015	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Daclatasvir (Daklinza®)
2015	National Evidence-based Healthcare Collaborating Agency (NECA)	[Handbook for clinical practice guideline developer]
2015	Canadian Agency for Drugs and Technologies in Health (CADTH)	Excimer laser and stenting in patients with distal peripheral arterial disease: a review of the clinical effectiveness, safety, and guidelines
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Pelareorep (Reolysin) with or without chemotherapy for metastatic malignant melanoma – second line
2015	Institute for Clinical Effectiveness and Health Policy (IECS)	Mechanical insufflation-exsufflation assisted coughing in neuromuscular diseases
2015	NIHR Health Technology Assessment programme	The impact of Cochrane Reviews: a mixed-methods evaluation of outputs from Cochrane Review Groups supported by the National Institute for Health Research
2015	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Defibrotide (Defitelio®)
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Pelareorep (Reolysin) in combination with chemotherapy for metastatic or recurrent squamous cell carcinoma of the head and neck – second line
2015	Institute for Clinical Effectiveness and Health Policy (IECS)	Cervical arthroplasty for degenerative intervertebral disc disease
2015	Basque Office for Health Technology Assessment (OSTEBA)	[Telemonitoring multi-pathological chronic patients with heart or lung disease. Evaluation of the implementation in Primary Care]
2015	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Tonsillectomy, adenoidectomy and adenotonsillectomy for obstructive sleep apnoea: review of clinical evidence and guidelines
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Apixaban and rivaroxaban for stroke prevention in atrial fibrillation: safety
2014	NIHR Health Services and Delivery Research programme	An ethnographic study of knowledge sharing across the boundaries between care processes, services and organisations: the contributions to safe hospital discharge
2014	Health Quality Ontario (HQO)	Health care for people approaching the end of life: an evidentiary framework
2014	HAYES, Inc.	ConstaVac CBCII blood conservation system (Stryker Corporation) for perioperative autotransfusion in total knee arthroplasty
2014	NIHR Health Technology Assessment programme	Changing eating behaviours to treat childhood obesity in the community using mandolean: the community mandolean randomised trial (COMMANDO), a pilot study
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Conjugate pneumococcal vaccine (13-Valent) for immunocompromised populations: a review of the clinical evidence
2014	NIHR Health Services and Delivery Research programme	The use of a collaborative structured methodology for the development of a multifaceted intervention programme for the management of asthma (the MIA project), tailored to the needs of children and families of South Asian origin: a community-based, participatory study
2014	Health Quality Ontario (HQO)	Cardiopulmonary resuscitation in patients with terminal illness: an evidence-based analysis
2014	HAYES, Inc.	Floseal (Baxter Healthcare Corporation) for hemostasis during cardiothoracic surgery
2014	Basque Office for Health Technology Assessment (OSTEBA)	[The application of GRADE in the development of a CPG on childhood asthma]
2014	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Arthroscopy for knee osteoarthritis: review of clinical evidence and guidelines
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Bronchial thermoplasty for severe asthma: clinical and cost-effectiveness, and guidelines
2014	NIHR Health Services and Delivery Research programme	Frequency of visual field testing when monitoring patients newly diagnosed with glaucoma: mixed methods and modelling
2014	Health Quality Ontario (HQO)	The determinants of place of death: an evidence-based analysis
2014	HAYES, Inc.	Floseal hemostatic matrix (Baxter Healthcare Corporation) for hemostasis during tonsillectomy or adenoidectomy
2014	Health Council of the Netherlands Gezondheidsraad (GR)	Penicillamine - Evaluation of the effects on reproduction, recommendation for classification
2014	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Herniorrhaphy for inguinal and femoral hernia: review of clinical evidence and guidelines
2014	Agency for Healthcare Research and Quality (AHRQ)	Smoking cessation interventions in pregnancy and postpartum care
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Disposable surgical gowns and wrappers: clinical and cost-effectiveness, and guidelines